Lung Cancer

Nivolumab and ipilimumab extend OS in NSCLC: CheckMate-227 trial

The combination of nivolumab plus low-dose ipilimumab led to a longer duration of overall survival (OS) versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC), independent of  PD-L1 expression level, according to a secondary analysis of the CheckMate 227 trial. In the phase III trial  presented here at ESMO Congress 2019 by Professor ...

Already a member?

Login to keep reading.

© 2021 the limbic